Austin M Tang1, Joshua Bakhsheshian2, Michelle Lin1, Casey A Jarvis1, Edith Yuan1, Ian A Buchanan2, Li Ding3, Ben A Strickland2, Eric Chang4, Gabriel Zada2, William J Mack2, Frank J Attenello2. 1. Keck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA. 2. Department of Neurological Surgery, Keck School of Medicine, University of Southern California, 1200 North State Street Suite 3300, Los Angeles, CA 90033, USA. 3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 North Soto Street, Los Angeles, CA 90032, USA. 4. Department of Radiation Oncology, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Los Angeles, CA 90033, USA.
Abstract
BACKGROUND: Stereotactic radiosurgery (SRS) is indicated for a spectrum of brain tumors and is often an outpatient procedure, though severe disease may precipitate inpatient treatment. Readmission following inpatient SRS for brain tumors is not well understood. OBJECTIVES: To characterize rate, associative factors, and predictors of SRS readmission. METHODS: Retrospective analysis of inpatients treated with SRS for brain neoplasms was conducted (2010-2014 Nationwide Readmissions Database). Diagnoses upon readmission were characterized. Associations with 30-day readmission were identified using multivariate analyses. RESULTS: Of 2,553 patients undergoing SRS, 390 were readmitted (15.3%) within 30 days. Leading readmission diagnoses were infectious or embolic. Neurological readmissions of intracerebral hemorrhage (2.1%) and cerebral edema (1.5%) were rare. Malignant tumors (OR=1.60, p=0.007) and discharge to facility (OR=1.41, p=0.004) were associated with readmission. CONCLUSION: Inpatients receiving SRS for brain tumors have a 15.3% 30-day readmission rate. Neurologic readmissions were rare, underscoring the neurological safety of SRS, even in sick inpatients.
BACKGROUND: Stereotactic radiosurgery (SRS) is indicated for a spectrum of brain tumors and is often an outpatient procedure, though severe disease may precipitate inpatient treatment. Readmission following inpatient SRS for brain tumors is not well understood. OBJECTIVES: To characterize rate, associative factors, and predictors of SRS readmission. METHODS: Retrospective analysis of inpatients treated with SRS for brain neoplasms was conducted (2010-2014 Nationwide Readmissions Database). Diagnoses upon readmission were characterized. Associations with 30-day readmission were identified using multivariate analyses. RESULTS: Of 2,553 patients undergoing SRS, 390 were readmitted (15.3%) within 30 days. Leading readmission diagnoses were infectious or embolic. Neurological readmissions of intracerebral hemorrhage (2.1%) and cerebral edema (1.5%) were rare. Malignant tumors (OR=1.60, p=0.007) and discharge to facility (OR=1.41, p=0.004) were associated with readmission. CONCLUSION: Inpatients receiving SRS for brain tumors have a 15.3% 30-day readmission rate. Neurologic readmissions were rare, underscoring the neurological safety of SRS, even in sick inpatients.
Authors: M J Glantz; B F Cole; P A Forsyth; L D Recht; P Y Wen; M C Chamberlain; S A Grossman; J G Cairncross Journal: Neurology Date: 2000-05-23 Impact factor: 9.910
Authors: Michael T Milano; Manju Sharma; Scott G Soltys; Arjun Sahgal; Kenneth Y Usuki; Jon-Michael Saenz; Jimm Grimm; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2018-03-29 Impact factor: 7.038
Authors: Alvin R Cabrera; Kyle C Cuneo; Annick Desjardins; John H Sampson; Frances McSherry; James E Herndon; Katherine B Peters; Karen Allen; Jenny K Hoang; Zheng Chang; Oana Craciunescu; James J Vredenburgh; Henry S Friedman; John P Kirkpatrick Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-29 Impact factor: 7.038